01 Jan No advantage of quadruple- or triple-class antiretroviral therapy as initial treatment in patients with very high viraemia
Posted at 00:00h
in
Authored by: Grijsen Marlous L., Holman Rebecca, Gras Luuk, Wit Ferdinand W. N. M., Hoepelman Andy I. M., van den Berk Guido E., de Wolf Frank, Prins Jan M.
In: ANTIVIRAL THERAPY 17(8), 2012, p.1609-1613
http://www.ncbi.nlm.nih.gov/pubmed/22909444